What is the price-to-earnings ratio of CureVac?
The price-earnings ratio of CureVac is currently 3.07.
CureVac P/S 2024
CureVac P/S
3.07
Ticker
CVAC
ISIN
NL0015436031
WKN
A2P71U
As of Dec 18, 2024, CureVac's P/S ratio stood at 3.07, a -91.16% change from the 34.72 P/S ratio recorded in the previous year.
The CureVac P/S history
CureVac Aktienanalyse
What does CureVac do?
CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding CureVac's P/S Ratio
CureVac's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing CureVac's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating CureVac's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in CureVac’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about CureVac stock
How has the price-earnings ratio of CureVac changed compared to last year?
The price-to-earnings ratio of CureVac has increased by -91.16% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of CureVac high compared to other companies?
Yes, the price-to-earnings ratio of CureVac is high compared to other companies.
How does an increase in the price-earnings ratio of CureVac affect the company?
An increase in the price-earnings ratio of CureVac would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of CureVac affect the company?
A decrease in the price-earnings ratio of CureVac would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of CureVac?
Some factors that influence the price-earnings ratio of CureVac are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does CureVac pay?
Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.
What is the dividend yield of CureVac?
The current dividend yield of CureVac is .
When does CureVac pay dividends?
CureVac pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CureVac?
CureVac paid dividends every year for the past 0 years.
What is the dividend of CureVac?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is CureVac located?
CureVac is assigned to the 'Health' sector.
Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CureVac from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did CureVac pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of CureVac in the year 2023?
In the year 2023, CureVac distributed 0 EUR as dividends.
In which currency does CureVac pay out the dividend?
The dividends of CureVac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CureVac stock can be added to a savings plan with the following providers: Scalable Capital
Andere Kennzahlen von CureVac
Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
